Cerus Corporation

Cerus Corporation specializes in ensuring the safety of the global blood supply through innovative pathogen reduction technologies, particularly its flagship INTERCEPT Blood System, which enhances transfusion safety for blood components. Founded in 1991, Cerus Corporation is based in Concord, US, and focuses on blood safety solutions. The company has undergone strategic evolution to enhance its product offerings, including the development of the INTERCEPT Blood System. The firm was founded by Laurence Corash, who has a notable history in the healthcare sector.

Cerus has successfully raised a total of USD 24. 30 mn over several funding rounds, with the most recent round being a VENTURE DEBT of USD 5. 00 mn in April 2019. The company has completed 8 deals to date.

Cerus Corporation primarily focuses on ensuring the safety of the global blood supply through its innovative product offerings. The company’s flagship product, the INTERCEPT Blood System, provides pathogen reduction technologies for platelets and plasma, effectively rendering blood components safe for transfusion by targeting harmful pathogens. This system has received regulatory approvals from both the FDA and CE, allowing it to be marketed and utilized in numerous countries, including the United States and European markets. Additionally, Cerus has developed the INTERCEPT Blood System for Cryoprecipitation, which produces Pathogen Reduced Cryoprecipitated Fibrinogen Complex for managing severe bleeding conditions.

Cerus caters to a diverse clientele, including blood centers, hospitals, and healthcare institutions that rely on safe blood components for patient care, thereby addressing critical healthcare needs across North America, Europe, and various international markets. Cerus Corporation generates revenue through the sales of its specialized blood safety technologies, primarily the INTERCEPT Blood System, which is integral to their business model. Transactions typically occur on a B2B basis, where Cerus partners with blood centers and healthcare facilities to provide its pathogen reduction systems and associated services. Pricing structures are designed to accommodate the varied needs of their clients, potentially involving direct purchases of the INTERCEPT products or long-term agreements for ongoing supply and support.

The company's revenue is bolstered by the increasing demand for safe blood products, driven by heightened awareness of transfusion safety and regulatory requirements in multiple regions. Through these strategic partnerships and sales agreements, Cerus effectively positions itself as a key player in the healthcare industry's efforts to enhance blood safety. Cerus Corporation is focused on expanding its product line and geographical reach to enhance growth opportunities. The company is currently designing new products within the INTERCEPT Blood System portfolio aimed at addressing additional pathogen reduction needs.

Cerus intends to broaden its market presence in Europe and Asia by 2025, leveraging recent funding to support these initiatives. The company's latest VENTURE DEBT round will be utilized to scale production capacity and facilitate market entry strategies.